OncoDaily IO· @OncoDailyIO · X·· 2 天前评分70
正文 · 机器翻译
🩸 ctDNA 能否在 MIBC 手术前捕捉治疗反应？
https://oncodaily.com/oncolibrary/immune-oncology/keynote-b15-ctdna
KEYNOTE-B15/EV-304 探索性分析：
ctDNA 清除率：EV + pembrolizumab 组为 82.1%，gemcitabine–cisplatin 组为 66.7%。
清除与更佳的 EFS 相关。
#ESMO2026 #OncoDaily #ESMO26 #KEYNOTEB15
120 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
4734O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上
ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin
https://esmocongress.esmo.orgNCT04700124NCT04700124按 - **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) 对上
- **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
https://esmocongress.esmo.org来源：OncoDaily IO · x.com